TABLE OF CONTENTS

APPENDICES

LIST OF TABLE

LIST OF FIGURES

CHAPTER IV

APPENDIX A

APPENDIX B

LIST OF ABBREVIATIONS

adr or ADR	Adriamycin
AO	Acridine orange
antiCD95/CD95L/FasL	CD95 ligand/Fas ligand
ATP	Adenosine triphosphate
CD56-PE	CD56-Phycoerythrin
$\Delta\Psi_m$	mitochondrial membrane potential
DAB	DNA-biotinylated-diaminobenzidine
DCHF-DA	2′,7′-dichlorofluorescein diacetate
DCHF	2′,7′-dichlorofluorescein
DCF	dichlorofluorescein
Dox	Doxorubicin
EDTA	Ethelenediaminetetra acetic acid
FITC	Fluoresceinisothiocyanate
GG918	Acridone carboxamide derivative
H&E	Hematoxyline and Eosin
ITLC	instant thin-layer chromatography
MDR	Multidrug resistance
MPE	Mamoa wood extract
MRP1	multidrug-associated Protein
MTT	3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium

	bromide
m.f.p.	Mammary fat pad
NCAM/CD56	myocyte-associated neural cell adhesion molecule
PI	Propidium iodide
Pgp	P-glycoprotein
PS	phosphatidylserine
RF	Resistance factor
ROI	Region-of-interest
ROS_i	Intracellular reactive oxygen species
Siamois®	The mixture of SRPE and MPE
s.c.	subcutaneous
SRPE	Siamois® red wine polyphenol extract
TUNEL	Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling
THP	Theprarubicin/pirarubicin
TW	Tumor weight
K562	human erythromyelogenous leukemic drug-sensitive cell
K562/*adr*	human erythromyelogenous leukemic drug-resistant cell
GLC4	human small cell lung carcinoma drug-sensitive cell
GLC4/*adr*	human small cell lung carcinoma drug-resistant cell
MDA-MB-435	human breast carcinoma cell